ArticleLiver cancer2025
Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update.
Abstract read
In one paragraph
Article in Liver cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Resection rates after conversion therapy for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Neoadjuvant therapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: an updated systematic review with meta-analysis.World journal of surgical oncology · 2025Pooled it
- Integrated single-cell multi-omics characterization reveals lipid-associated macrophage-mediated immunosuppression in neoadjuvant immunotherapy of hepatocellular carcinoma.Nature communications · 2026Trial
- Conversion Resection or Direct Resection for Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicentre Study.Liver cancer · 2026Article
- Article
- The Evolving Role of Immunotherapy in the Treatment with Curative Purpose of Early, Intermediate and Advanced Stage Hepatocellular Carcinoma.Current oncology (Toronto, Ont.) · 2026Review
- Immunotherapy-Based Conversion to Curative-Intent Treatment in Hepatocellular Carcinoma: A Multidisciplinary Framework.Cancers · 2026Review
- Personalised decision-making in hepatocellular carcinoma: conceptual evolution over two decades.BJS open · 2026Review
- Adjuvant systemic therapy versus active surveillance after resection following conversion therapy for hepatocellular carcinoma: a propensity score matched study.BMC medicine · 2026Article
- Efficacy and safety of transarterial chemoembolization (TACE) with tislelizumab and tyrosine kinase inhibitors versus TACE for intermediate and advanced HCC.Journal of cancer research and clinical oncology · 2026Article
- Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with vascular invasion: A systematic review and meta-analysis.Oncology letters · 2026Article
- Prognostic Value of Pathological Response After Conversion Therapy and Salvage Surgery in Unresectable Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Antitumor efficacy and molecular mechanism of lenvatinib combined with vitamin K2 against hepatocellular carcinoma.World journal of surgical oncology · 2026Article
- Hepatic arterial infusion chemotherapy plus sintilimab as conversion therapy for locally advanced hepatocellular carcinoma: a single-center phase II trial.International journal of surgery (London, England) · 2026Article
- Comparable Long-Term Survival After Curative Hepatectomy for Solitary Large (5-10 cm) versus Giant (≥10 cm) Hepatocellular Carcinoma: A Retrospective Study.Journal of hepatocellular carcinoma · 2026Article
- Prognostic Value of the SEA Score in Double-Negative DCP/AFP Unresectable HCC with Triple Therapy.Journal of hepatocellular carcinoma · 2026Article
- Sequential Multimodal Therapy for Conversion Resection of Stage IIIa Hepatocellular Carcinoma: A Case Report.Journal of hepatocellular carcinoma · 2026Article
- Neoadjuvant therapy for hepatocellular carcinoma: emerging combinations and biomarker challenges.Frontiers in immunology · 2026Review
- Article
- The SAGES scoring model leads to personalized treatment via the combination of TACE, TKIs and ICIs for unresectable hepatocellular carcinoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Xinyu BiDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Haitao ZhaoDepartment of Liver Surgery, Peking Union Medical College (PUMC) Hospital/PUMC/Chinese Academy of Medical Sciences, Beijing, China.
Hong ZhaoDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Guangming LiDepartment of Hepatobiliary Surgery, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Xiaodong WangDepartments of Interventional Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
Bo ChenDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wen ZhangDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xu CheDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Zhen HuangDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yue HanDepartment of Interventional Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Liming JiangDepartment of Diagnostic Imaging, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yongkun SunDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhengqiang YangDepartment of Interventional Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jianguo ZhouDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yefan ZhangDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhenyu ZhuDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital/ Chinese PLA Medical School, Beijing, China.
Minshan ChenDepartment of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Shuqun ChengThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Jianqiang CaiDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a common malignancy in China, with high recurrence rate and low resection rate among patients first diagnosed. Preoperative treatments including neoadjuvant and conversion therapy have the potential to overcome these challenges. In December 2021,
Indexed as
ConsensusConversion therapyHepatocellular carcinomaNeoadjuvant therapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.